Company Research
Whether you are exploring new sales opportunities or researching a new investment, FirstRain provides unique insight into important developments for Baxter International Inc. (BAX). You can receive reports or configure the research engine for yourself.
Report On:
Baxter International Inc. (BAX)
HEALTHCARE - Health Services - Medical Instruments & Supplies
Generated: Thursday September 15, 2011 04:05 AM
|
|
||||||||||||||||||
Quotes About Baxter International Inc.
-
Baxter subdivision may hook-up to Angus sewage plant
Frankly, they can be a pain to operate,"
- Ron Henderson -
Lawyer: Hepatitis C outbreak doesn't happen if drug makers sell smaller anesthetic vials
Over and over again, doctors and nurses made mistakes that could have been prevented if only they sold 10- and 20-milliliter vials,"
- Rick Friedman -
Biotechnology: Baxter to Acquire to Privately Held Baxa Corporation
With these new offerings, Baxter will be able to provide a comprehensive solution to fulfill the majority of patients' nutritional requirements and increase efficiency in the pharmacy"
- Robert M. Davis -
Biopharma Venture Funds Are Stepping Up Where VC Firms Are Stepping Out
We typically make an initial investment in the $4 million to $10 million range and participate in follow-on financings, so that total amount could potentially reach $20 million to $25 million," -
Baxter BioPharma Solutions' Completes Capacity Expansion at Halle Facility to Meet Growing Demand for Cytotoxic Manufacturing
This latest investment clearly demonstrates our commitment to meeting our clients' increasing need for high-quality, cytotoxic drug production,"
- Burkhard Wichert
Latest Company Intelligence
-
Baxter Sues Teva to Enforce Liability Agreement Over Some Hepatitis Cases
Bloomberg.com | Aug 31,'11
Baxter International Inc., the maker of blood products and intravenous drugs, sued Teva Pharmaceutical Industries Ltd. (TEVA) to enforce an indemnity agreement over claims the drugmakers sold the anesthetic propofol in a way that led some patients to develop hepatitis. Baxter contends in a Delaware Chancery Court lawsuit that an arbitration panel ruled in June Teva was bound by an -
JAMA Article Begs Key Questions About Case of Contaminated Heparin
Health Care Renewal | Aug 31,'11
There was a recent reminder of the case of the tainted heparin, which begged more questions than it answered. (A case summary is appended to the end of this post, and nearly all our posts are here .) The case is of fundamental importance because it involves the failure of pharmaceutical companies to fulfill their core mission, to supply pure, unadulterated drugs. Three years later, -
Baxter Intl to buy privately held Baxa for $380 M
CNBC | Aug 25,'11
DEERFIELD, Ill. - Drug and medical device maker Baxter International Inc. said Thursday it will buy privately held Baxa Corp. in a deal valued at about $380 million. Baxter, based in Deerfield, Ill., said the deal will complement its portfolio of nutrition products and drug delivery systems. Baxa had about $150 million in sales last year. Baxter expects the acquisition to be -
UPDATE 1-Baxter buying drug delivery company for $380 mln
Reuters | Aug 25,'11
Thu Aug 25, 2011 8:05am EDT * Baxter buying privately held Baxa Corp * Sees deal reducing 2012 profit, helping from 2013 on Aug 25 (Reuters) - Baxter International Inc ( BAX. N ) said it struck a deal to buy privately held Baxa Corp, a drug delivery company, for $380 million in cash. -
Teva Not Responsible for Hepatitis Outbreak, Lawyer Says
Bloomberg Businessweek | Aug 19,'11
(Updates with excerpts from opening statements starting in third paragraph.) Aug. 19 (Bloomberg) -- Teva Pharmaceutical Industries Ltd., the world's biggest generic-drug maker, isn't responsible for a 2008 hepatitis outbreak in Nevada blamed on the misuse of vials of the anesthetic propofol, a lawyer for the company said. Patients developed hepatitis C after receiving propofol during
FirstRain customers use intelligent business search to find actionable insights about companies, management, and industries. You can review company briefs, quickly research a new idea or opportunity, generate personalized industry reports, or set up alerts on reasons to call. Be sure to view our sample reports below.
